NeoGenomics Buys Oncology Lab Genoptix

NeoGenomics Buys Oncology Lab Genoptix

It’s been two years since NeoGenomics, Inc. (NASDAQ: NEO) announced an acquisition, but now the time clock has been reset. On October 23rd, the cancer-focused genetic testing company made public its purchase of Genoptix, Inc., a privately held clinical oncology laboratory specializing in hematology and solid tumor testing. Genoptix has well-established relationships with community oncology practices, a sales force and pathologists that are experienced in serving oncologists, and customized reports that are considered to be the gold standard among community oncologists. Oncology practices are an important, and under-penetrated, channel for promoting NeoGenomics’ capabilities in... Read More »